[{"orgOrder":0,"company":"eXIthera Pharmaceutical","sponsor":"Cadrenal Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Frunexian","moa":"F11a","graph1":"Hematology","graph2":"Phase I","graph3":"eXIthera Pharmaceutical","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"eXIthera Pharmaceutical \/ Cadrenal Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"eXIthera Pharmaceutical \/ Cadrenal Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals for Frunexian

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Florida Innovation
                          Not Confirmed
                          Florida Innovation
                          Not Confirmed

                          Details : The Acquisition enhances the Company’s pipeline by adding novel assets, including frunexian, a first-in-class, Phase 2-ready IV Factor XIa inhibitor in acute and chronic anticoagulation settings.

                          Product Name : EP-7041

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          September 15, 2025

                          Lead Product(s) : Frunexian

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase I

                          Sponsor : Cadrenal Therapeutics

                          Deal Size : $15.0 million

                          Deal Type : Acquisition

                          blank